bioAffinity Technologies Faces Delisting Notice
Ticker: BIAFW · Form: 8-K · Filed: May 30, 2025 · CIK: 1712762
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
Related Tickers: BIAF
TL;DR
BIAF got a notice about possibly getting delisted. Big trouble.
AI Summary
bioAffinity Technologies, Inc. filed an 8-K on May 30, 2025, reporting a notice of delisting or failure to satisfy continued listing rules as of May 27, 2025. The company is incorporated in Delaware and its principal executive offices are located in San Antonio, Texas.
Why It Matters
This filing indicates potential delisting from a stock exchange, which could significantly impact the liquidity and valuation of the company's shares.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading and investor confidence.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- May 27, 2025 (date) — Earliest event reported
- May 30, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- San Antonio, Texas (location) — Principal executive offices
FAQ
What specific listing rule or standard has bioAffinity Technologies, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that was not met, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the earliest date the delisting issue was reported?
The earliest event reported in the filing occurred on May 27, 2025.
When was this Form 8-K filed with the SEC?
This Form 8-K was filed on May 30, 2025.
What is the company's principal business address?
The company's principal executive offices are located at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.
What is the company's state of incorporation?
The company is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 30, 2025 regarding bioAffinity Technologies, Inc. (BIAFW).